Shots:
- The US FDA has received the sBLA of Bizengri (zenocutuzumab-zbco) for the treatment of adults with advanced unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion
- sBLA was supported by eNRGy study assessing Bizengri in pts with NRG1 fusion-positive cancers, incl. cholangiocarcinoma, showing an ORR of 36.8% & mDOR of 12.9mos. per BICR, in the cholangiocarcinoma cohort
- Based on these data, NCCN added Bizengri to guidelines for biliary tract cancers as Category 2A subsequent therapy & Category 2B frontline option for NRG1 fusion–positive cholangiocarcinoma
Ref: PRnewswire | Image: Partner |Press Release
Related News: Daiichi Sankyo and Merck Receive FDA’s Priority Review for Ifinatamab Deruxtecan (I-DXd) to Treat ES-SCLC
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
